Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28524159
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28524159
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Br+J+Cancer
2017 ; 117
(1
): 1-7
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Hallmarks of response to immune checkpoint blockade
#MMPMID28524159
Cogdill AP
; Andrews MC
; Wargo JA
Br J Cancer
2017[Jun]; 117
(1
): 1-7
PMID28524159
show ga
Unprecedented advances have been made in the treatment of cancer through the use
of immune checkpoint blockade, with approval of several checkpoint blockade
regimens spanning multiple cancer types. However, responses to this form of
therapy are not universal, and insights are clearly needed to identify optimal
biomarkers of response and to combat mechanisms of therapeutic resistance. A
working knowledge of the hallmarks of cancer yields insight into responses to
immune checkpoint blockade, although the focus of this is rather tumour-centric
and additional factors are pertinent, including host immunity and environmental
influences. Herein, we describe the foundation for pillars and hallmarks of
response to immune checkpoint blockade, with a discussion of their relevance to
immune monitoring and mechanisms of resistance. Evolution of this understanding
will ultimately help guide treatment strategies to enhance therapeutic responses.
|*Gene Expression Regulation, Neoplastic
[MESH]
|Antibodies, Monoclonal, Humanized/therapeutic use
[MESH]
free
free
free
